TY - JOUR
T1 - Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes
AU - Watanabe, Hitoshi
AU - Du, Wen
AU - Son, Jinsook
AU - Sui, Lina
AU - Asahara, Shun Ichiro
AU - Kurland, Irwin J.
AU - Kuo, Taiyi
AU - Kitamoto, Takumi
AU - Miyachi, Yasutaka
AU - de Cabo, Rafael
AU - Accili, Domenico
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Sulfonylureas (SUs) are effective and affordable antidiabetic drugs. However, chronic use leads to secondary failure, limiting their utilization. Here, we identify cytochrome b5 reductase 3 (Cyb5r3) down-regulation as a mechanism of secondary SU failure and successfully reverse it. Chronic exposure to SU lowered Cyb5r3 abundance and reduced islet glucose utilization in mice in vivo and in ex vivo murine islets. Cyb5r3 β cell-specific knockout mice phenocopied SU failure. Cyb5r3 engaged in a glucose-dependent interaction that stabilizes glucokinase (Gck) to maintain glucose utilization. Hence, Gck activators can circumvent Cyb5r3-dependent SU failure. A Cyb5r3 activator rescued secondary SU failure in mice in vivo and restored insulin secretion in ex vivo human islets. We conclude that Cyb5r3 is a key factor in the secondary failure to SU and a potential target for its prevention, which might rehabilitate SU use in diabetes.
AB - Sulfonylureas (SUs) are effective and affordable antidiabetic drugs. However, chronic use leads to secondary failure, limiting their utilization. Here, we identify cytochrome b5 reductase 3 (Cyb5r3) down-regulation as a mechanism of secondary SU failure and successfully reverse it. Chronic exposure to SU lowered Cyb5r3 abundance and reduced islet glucose utilization in mice in vivo and in ex vivo murine islets. Cyb5r3 β cell-specific knockout mice phenocopied SU failure. Cyb5r3 engaged in a glucose-dependent interaction that stabilizes glucokinase (Gck) to maintain glucose utilization. Hence, Gck activators can circumvent Cyb5r3-dependent SU failure. A Cyb5r3 activator rescued secondary SU failure in mice in vivo and restored insulin secretion in ex vivo human islets. We conclude that Cyb5r3 is a key factor in the secondary failure to SU and a potential target for its prevention, which might rehabilitate SU use in diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85147235152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147235152&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.abq4126
DO - 10.1126/scitranslmed.abq4126
M3 - Article
C2 - 36724243
AN - SCOPUS:85147235152
SN - 1946-6234
VL - 15
SP - eabq4126
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 681
ER -